The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice

Cancer Chemotherapy and Pharmacology

Volumn 57, Issue 6, 2006, Pages 819-825

  Press, Rogier R ^a   Buckle, Tessa ^a   Beijnen, Jos H ^b,c   Van Tellingen, Olaf ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

High performance liquid chromatography; Navelbine; P glycoprotein; Pharmacokinetics; Ritonavir

Indexed keywords

CYTOCHROME P450 3A; DEACETYLVINBLASTINE; GLYCOPROTEIN P; NAVELBINE; RITONAVIR; VINCA ALKALOID;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANNULATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG DISPOSITION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; ENZYME METABOLISM; FECES ANALYSIS; FEMALE; FIRST PASS EFFECT; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ION EXCHANGE CHROMATOGRAPHY; JUGULAR VEIN; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; SPECIES COMPARISON; VASCULAR ACCESS; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP3A; FECES; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; P-GLYCOPROTEINS; VINBLASTINE;

EID: 33645734606     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0088-2     Document Type: Article

References (28)

1. Adams DJ, Knick VC (1995) P-glycoprotein mediated resistance to 5′-nor-anhydro-vinblastine (Navelbine). Invest New Drugs 13:13-21
2. Bardelmeijer HA, Buckle T, Ouwehand M, Beijnen JH, Schellens JH, van Tellingen O (2003) Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples. Lab Anim 37:181-187
3. Bardelmeijer HA, Ouwehand M, Buckle T, Huisman MT, Schellens JH, Beijnen JH, van Tellingen O (2002) Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 62:6158-6164
4. Bardelmeijer HA, van Tellingen O, Schellens JH, Beijnen JH (2000) The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery. Invest New Drugs 18:231-241
5. Benet LZ, Izumi T, Zhang Y, Silverman JA, Wacher VJ (1999) Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Controlled Release 62:25-31
6. Binet S, Chaineau E, Fellous A, Lataste H, Krikorian A, Couzinier JP, Meininger V (1990) Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules. Int J Cancer 46:262-266
7. Chiou WL, Chung SM, Wu TC, Ma C (2001) A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int J Clin Pharmacol Ther 39:93-101
8. Depierre A, Freyer G, Jassem J, Orfeuvre H, Ramlau R, Lemarie E, Koralewski P, Mauriac L, Breton JL, Delozier T, Trillet-Lenoir V (2001) Oral vinorelbine: feasibility and safety profile. Ann Oncol 12:1677-1681
9. Domenech GH, Vogel CL (2001) A review of vinorelbine in the treatment of breast cancer. Clin Breast Cancer 2:113-128
10. Edelman MJ (2001) New directions in the treatment of non-small cell lung cancer: an overview. Oncologist 6:1-3
11. Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, Imadalou K, Trillet-Lenoir V (2003) Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 21:35-40
12. Fromm MF (2003) Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest 33 Suppl 2:6-9
13. Jehl F, Quoix E, Leveque D, Pauli G, Breillout F, Krikorian A, Monteil H (1991) Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. Cancer Res 51:2073-2076
14. Kajita J, Kuwabara T, Kobayashi H, Kobayashi S (2000) CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos 28:1121-1127
15. Leveque D, Jehl F (1996) Clinical pharmacokinetics of vinorelbine. Clin Pharmacokinet 31:184-197
16. Leveque D, Wisniewski S, Renault C, Peter JD, Le Corre P, Monteil H, Jehl F (2003) The effect of rifampin on the pharmacokinetics of vinorelbine in the micropig. Anticancer Res 23:2741-2744
17. Lin JH, Yamazaki M (2003) Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev 35:417-454
18. Ling V (1997) Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 40:S3-S8
19. Myer MS, Joone G, Chasen MR, van Rensburg CE (1999) The chemosensitizing potential of GF120918 is independent of the magnitude of P-glycoprotein-mediated resistance to conventional chemotherapeutic agents in a small cell lung cancer line. Oncol Rep 6:217-218
20. Ngan VK, Bellman K, Hill BT, Wilson L, Jordan MA (2001) Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol 60:225-232
21. Proost JH, Meijer DK (1992) MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 22:155-163
22. Rowinsky EK, Noe DA, Trump DL, Winer EP, Lucas VS, Wargin WA, Hohneker JA, Lubejko B, Sartorius SE, Ettinger DS, . (1994) Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. J Clin Oncol 12:1754-1763
23. Shepard RL, Cao J, Starling JJ, Dantzig AH (2003) Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int J Cancer 103:121-125
24. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035
25. van Asperen J, van Tellingen O, Beijnen JH (2000) The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab Dispos 28:264-267
26. van Heeswijk RP, Veldkamp A, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM (2001) Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther 6:201-229
27. van Tellingen O, Kuijpers A, Beijnen JH, Baselier MR, Burghouts JT, Nooyen WJ (1992) Bio-analysis of vinorelbine by high-performance liquid chromatography with fluorescence detection. J Chromatogr 573:328-332
28. van Tellingen O, Kuijpers AV, Beijnen JH, Nooijen WJ, Bult A (1993) Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography. Invest New Drugs 11:141-150